Drug intelligence / Profile preview

WXD171-Csa1

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Administration: Oral

Overview

WXD171-Csa1 is a genetically engineered probiotic vaccine candidate designed for oral administration to protect against Staphylococcus aureus infections. It utilizes a specific strain of Limosilactobacillus reuteri (WXD171) as a live bacterial delivery vehicle, which has been modified using the pNZ8148 expression plasmid system to display the S. aureus Csa1 antigen on its cell surface. This live biotherapeutic approach aims to elicit both mucosal and systemic immune responses, providing a prophylactic strategy against localized infections, such as pneumonia and skin infections, as well as systemic conditions like sepsis. The vaccine leverages the natural probiotic properties of L. reuteri, including its tolerance of the gastrointestinal environment and adhesion ability, to deliver bacterial antigens directly to gut-associated lymphoid tissues.

Other names: Limosilactobacillus reuteri WXD171-Csa1

Targets

Csa1 (Conserved Staphylococcal Antigen 1)

Beyond the preview

Go deeper on WXD171-Csa1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WXD171-Csa1.

Explore the full profile